Literature DB >> 28502000

Reverse Phase Protein Microarrays.

Elisa Baldelli1, Valerie Calvert1, Alex Hodge1, Amy VanMeter1, Emanuel F Petricoin1, Mariaelena Pierobon2.   

Abstract

While genes and RNA encode information about cellular status, proteins are considered the engine of the cellular machine, as they are the effective elements that drive all cellular functions including proliferation, migration, differentiation, and apoptosis. Consequently, investigations of the cellular protein network are considered a fundamental tool for understanding cellular functions.Alteration of the cellular homeostasis driven by elaborate intra- and extracellular interactions has become one of the most studied fields in the era of personalized medicine and targeted therapy. Increasing interest has been focused on developing and improving proteomic technologies that are suitable for analysis of clinical samples. In this context, reverse-phase protein microarrays (RPPA) is a sensitive, quantitative, high-throughput immunoassay for protein analyses of tissue samples, cells, and body fluids.RPPA is well suited for broad proteomic profiling and is capable of capturing protein activation as well as biochemical reactions such as phosphorylation, glycosylation, ubiquitination, protein cleavage, and conformational alterations across hundreds of samples using a limited amount of biological material. For these reasons, RPPA represents a valid tool for protein analyses and generates data that help elucidate the functional signaling architecture through protein-protein interaction and protein activation mapping for the identification of critical nodes for individualized or combinatorial targeted therapy.

Entities:  

Keywords:  Cell lysates; Immunostaining; Proteomics; Reverse-phase protein microarray; Tissue lysates

Mesh:

Year:  2017        PMID: 28502000     DOI: 10.1007/978-1-4939-6990-6_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  20 in total

1.  The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Authors:  Erika Parasido; George S Avetian; Aisha Naeem; Garrett Graham; Michael Pishvaian; Eric Glasgow; Shaila Mudambi; Yichien Lee; Chukwuemeka Ihemelandu; Muhammad Choudhry; Ivana Peran; Partha P Banerjee; Maria Laura Avantaggiati; Kirsten Bryant; Elisa Baldelli; Mariaelena Pierobon; Lance Liotta; Emanuel Petricoin; Stanley T Fricke; Aimy Sebastian; Joseph Cozzitorto; Gabriela G Loots; Deepak Kumar; Stephen Byers; Eric Londin; Analisa DiFeo; Goutham Narla; Jordan Winter; Jonathan R Brody; Olga Rodriguez; Chris Albanese
Journal:  Mol Cancer Res       Date:  2019-06-04       Impact factor: 5.852

2.  Functional and biological heterogeneity of KRASQ61 mutations.

Authors:  Minh V Huynh; G Aaron Hobbs; Antje Schaefer; Mariaelena Pierobon; Leiah M Carey; J Nathaniel Diehl; Jonathan M DeLiberty; Ryan D Thurman; Adelaide R Cooke; Craig M Goodwin; Joshua H Cook; Lin Lin; Andrew M Waters; Naim U Rashid; Emanuel F Petricoin; Sharon L Campbell; Kevin M Haigis; Diane M Simeone; Costas A Lyssiotis; Adrienne D Cox; Channing J Der
Journal:  Sci Signal       Date:  2022-08-09       Impact factor: 9.517

3.  P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.

Authors:  Kevin H Lin; Justine C Rutter; Abigail Xie; Shane T Killarney; Camille Vaganay; Chaima Benaksas; Frank Ling; Gaetano Sodaro; Paul-Arthur Meslin; Christopher F Bassil; Nina Fenouille; Jacob Hoj; Rachel Washart; Hazel X Ang; Christian Cerda-Smith; Paul Chaintreuil; Arnaud Jacquel; Patrick Auberger; Antoine Forget; Raphael Itzykson; Min Lu; Jiaxing Lin; Mariaelena Pierobon; Zhecheng Sheng; Xinghai Li; Ashutosh Chilkoti; Kouros Owzar; David A Rizzieri; Timothy S Pardee; Lina Benajiba; Emanuel Petricoin; Alexandre Puissant; Kris C Wood
Journal:  Nat Cancer       Date:  2022-06-06

4.  Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.

Authors:  Özgün Le Roux; Nicole L K Pershing; Erin Kaltenbrun; Nicole J Newman; Jeffrey I Everitt; Elisa Baldelli; Mariaelena Pierobon; Emanuel F Petricoin; Christopher M Counter
Journal:  Elife       Date:  2022-09-07       Impact factor: 8.713

5.  A Multiplexed Mass Spectrometry-Based Assay for Robust Quantification of Phosphosignaling in Response to DNA Damage.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Rick Saul; Jan A Kaczmarczyk; Regine M Schoenherr; Heather D Moore; Corey Jones-Weinert; Richard G Ivey; Chenwei Lin; Tara Hiltke; Kerryn W Reding; Gordon Whiteley; Pei Wang; Amanda G Paulovich
Journal:  Radiat Res       Date:  2018-02-23       Impact factor: 2.841

6.  Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Authors:  Kirsten L Bryant; Clint A Stalnecker; Daniel Zeitouni; Jennifer E Klomp; Sen Peng; Andrey P Tikunov; Venugopal Gunda; Mariaelena Pierobon; Andrew M Waters; Samuel D George; Garima Tomar; Björn Papke; G Aaron Hobbs; Liang Yan; Tikvah K Hayes; J Nathaniel Diehl; Gennifer D Goode; Nina V Chaika; Yingxue Wang; Guo-Fang Zhang; Agnieszka K Witkiewicz; Erik S Knudsen; Emanuel F Petricoin; Pankaj K Singh; Jeffrey M Macdonald; Nhan L Tran; Costas A Lyssiotis; Haoqiang Ying; Alec C Kimmelman; Adrienne D Cox; Channing J Der
Journal:  Nat Med       Date:  2019-03-04       Impact factor: 53.440

7.  Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.

Authors:  Haisheng Zhang; Antje Schaefer; Channing J Der; Adam J Bass; Yichen Wang; Richard G Hodge; Devon R Blake; J Nathaniel Diehl; Alex G Papageorge; Matthew D Stachler; Jennifer Liao; Jin Zhou; Zhong Wu; Fahire G Akarca; Leonie K de Klerk; Sarah Derks; Mariaelena Pierobon; Katherine A Hoadley; Timothy C Wang; George Church; Kwok-Kin Wong; Emanuel F Petricoin; Adrienne D Cox; Douglas R Lowy
Journal:  Cancer Discov       Date:  2019-11-26       Impact factor: 38.272

8.  Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer.

Authors:  G Aaron Hobbs; Nicole M Baker; Anne M Miermont; Ryan D Thurman; Mariaelena Pierobon; Timothy H Tran; Andrew O Anderson; Andrew M Waters; J Nathaniel Diehl; Bjoern Papke; Richard G Hodge; Jennifer E Klomp; Craig M Goodwin; Jonathan M DeLiberty; Junning Wang; Raymond W S Ng; Prson Gautam; Kirsten L Bryant; Dominic Esposito; Sharon L Campbell; Emanuel F Petricoin; Dhirendra K Simanshu; Andrew J Aguirre; Brian M Wolpin; Krister Wennerberg; Udo Rudloff; Adrienne D Cox; Channing J Der
Journal:  Cancer Discov       Date:  2019-10-24       Impact factor: 38.272

9.  Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens.

Authors:  Allison L Hunt; Nicholas W Bateman; Waleed Barakat; Sasha Makohon-Moore; Brian L Hood; Kelly A Conrads; Ming Zhou; Valerie Calvert; Mariaelena Pierobon; Jeremy Loffredo; Tracy J Litzi; Julie Oliver; Dave Mitchell; Glenn Gist; Christine Rojas; Brian Blanton; Emma L Robinson; Kunle Odunsi; Anil K Sood; Yovanni Casablanca; Kathleen M Darcy; Craig D Shriver; Emanuel F Petricoin; Uma N M Rao; G Larry Maxwell; Thomas P Conrads
Journal:  iScience       Date:  2021-06-21

10.  Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN.

Authors:  Marta Codrich; Emiliano Dalla; Catia Mio; Giulia Antoniali; Matilde Clarissa Malfatti; Stefania Marzinotto; Mariaelena Pierobon; Elisa Baldelli; Carla Di Loreto; Giuseppe Damante; Giovanni Terrosu; Carlo Ennio Michele Pucillo; Gianluca Tell
Journal:  J Exp Clin Cancer Res       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.